GLP-1 and Psoriasis: Can Semaglutide & Tirzepatide Improve Skin Conditions?

The psoriasis-obesity connection

Psoriasis is an autoimmune skin condition affecting over 8 million Americans, causing red, scaly, itchy plaques on the skin. What many people do not realize is that psoriasis and obesity are tightly linked. People with obesity are nearly twice as likely to develop psoriasis, and those with psoriasis are more likely to have obesity.

This connection is not coincidental. Fat tissue produces pro-inflammatory cytokines — particularly IL-6 and TNF-alpha — that fuel the same inflammatory pathways driving psoriasis. The IL-17/IL-23 axis, which is the primary target of modern psoriasis biologics, is also activated by obesity-related inflammation.

This is where semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) enter the picture. By reducing obesity-related inflammation and directly modulating immune cell activity through GLP-1 receptors, these medications may offer a new approach to managing psoriatic disease.

How GLP-1 medications may help psoriasis

1. Weight loss reduces inflammatory burden

Losing 10 to 20 percent of body weight dramatically reduces the inflammatory cytokines produced by fat tissue. Studies have shown that bariatric surgery patients who lose significant weight often see psoriasis improvement. GLP-1 medications produce similar weight loss without surgery.

2. Direct anti-inflammatory effects on immune cells

GLP-1 receptors are found on immune cells involved in psoriasis, including T-cells and macrophages. Activating these receptors shifts immune cells from a pro-inflammatory to an anti-inflammatory state, potentially calming the immune overactivity that drives psoriasis.

3. Modulation of the IL-17/IL-23 axis

The IL-17/IL-23 axis is the central inflammatory pathway in psoriasis. Obesity activates this pathway through fat-derived cytokines. By reducing obesity and directly modulating immune cell behavior, GLP-1 medications may dampen IL-17/IL-23 signaling and reduce psoriatic inflammation.

4. Improved insulin sensitivity

Insulin resistance is common in both obesity and psoriasis. High insulin levels increase IGF-1, which promotes skin cell proliferation (the hallmark of psoriatic plaques). GLP-1 medications improve insulin sensitivity, potentially reducing this proliferative signal.

5. Reduced systemic oxidative stress

Oxidative stress contributes to psoriasis flares. GLP-1 receptor activation increases antioxidant defenses in cells, reducing the oxidative damage that can trigger and worsen psoriatic lesions.

What the research shows

Case reports and case series

Multiple case reports describe patients with psoriasis who experienced significant improvement after starting GLP-1 medications for weight loss or diabetes. In some cases, psoriatic plaques that had been resistant to traditional treatments cleared substantially after 3 to 6 months of GLP-1 therapy.

Observational studies

A 2025 retrospective study analyzed 1,200 patients with psoriasis who were also overweight or obese. Those who started GLP-1 receptor agonists had a 35 percent reduction in psoriasis flare-ups and a 28 percent reduction in topical steroid use over 12 months compared to matched controls who did not take GLP-1 medications.

The Springer Nature review (2026)

A comprehensive 2026 narrative review in Rheumatology International examined the role of GLP-1 receptor agonists in psoriatic disease. The authors concluded that obesity and psoriatic inflammation share common pathways through the IL-17/IL-23 axis, providing a "theoretical biological rationale" for GLP-1 RA use in psoriasis. They noted that while direct clinical evidence remains limited, the early data is "encouraging."

GLP-1 and psoriatic arthritis

Psoriatic arthritis (PsA) affects up to 30 percent of people with psoriasis, causing joint pain, stiffness, and swelling. The anti-inflammatory effects of GLP-1 medications may benefit PsA through:

• Reduced systemic inflammation (lower CRP, IL-6, TNF-alpha)
• Weight loss reducing mechanical stress on joints
• Direct immune cell modulation in synovial tissue
• Improved insulin sensitivity reducing inflammatory signaling

Case reports describe patients with PsA who experienced reduced joint pain and swelling after starting GLP-1 medications. While this is not yet a recognized treatment for PsA, the dual benefit of weight loss and inflammation reduction makes GLP-1 therapy particularly attractive for patients with PsA and obesity.

GLP-1 vs. psoriasis biologics

GLP-1 medications are not a replacement for psoriasis biologics in severe cases. However, for people with mild to moderate psoriasis and obesity, GLP-1 treatment may provide meaningful improvement while also addressing weight and metabolic health.

Who might benefit from GLP-1 for psoriasis?

• People with psoriasis and BMI 27 or higher
• People with psoriatic arthritis and obesity
• People whose psoriasis worsened with weight gain
• People who have metabolic syndrome alongside psoriasis
• People who cannot afford or access psoriasis biologics
• People looking for a treatment that addresses both weight and skin

What to discuss with your doctors

If you have psoriasis and are considering GLP-1 treatment, coordinate between your dermatologist and your GLP-1 prescriber:

• Ask your dermatologist if weight loss might improve your psoriasis
• Discuss whether GLP-1 treatment could complement your current psoriasis treatment
• Plan to monitor your psoriasis during GLP-1 treatment
• Do not stop psoriasis medications without consulting your dermatologist
• Ask about potential interactions between GLP-1 and psoriasis treatments

Frequently asked questions

Can GLP-1 medications help with psoriasis?

Early research suggests GLP-1 medications may improve psoriasis through anti-inflammatory effects and weight loss. Obesity is a known trigger for psoriasis, and the IL-17/IL-23 inflammatory pathway shared by both conditions may be modulated by GLP-1 receptor activation. Clinical evidence is still limited but encouraging.

Does semaglutide improve psoriatic arthritis?

Case reports and small studies suggest semaglutide may reduce joint pain and inflammation in psoriatic arthritis. The anti-inflammatory effects of GLP-1 medications, combined with weight loss that reduces joint stress, may provide dual benefits for psoriatic disease.

Should I take GLP-1 medications for psoriasis?

GLP-1 medications are not approved for psoriasis treatment. However, if you have obesity or overweight and also have psoriasis, GLP-1 treatment may improve both conditions simultaneously. Talk to your dermatologist and your GLP-1 provider about a coordinated treatment approach.

How does obesity affect psoriasis?

Obesity increases psoriasis severity through chronic inflammation, immune system dysregulation, and shared inflammatory pathways (IL-17/IL-23 axis). Fat tissue produces inflammatory cytokines that worsen psoriasis. Weight loss through GLP-1 medications may reduce this inflammatory burden.

Conclusion

The connection between GLP-1 medications and psoriasis represents an exciting frontier in dermatology and metabolic medicine. By addressing both obesity and the inflammatory pathways that drive psoriatic disease, GLP-1 receptor agonists may offer a dual-action approach for people struggling with both conditions. While more clinical research is needed, the early evidence is promising. If you have psoriasis and obesity, GLP-1 treatment could improve your skin, your joints, your weight, and your metabolic health all at once. Check your eligibility with a telehealth provider today.